Soon after Sanofi Pharmaceuticals’ Inc. August 2012 launch of the biologic drug ziv-aflibercept (brand name Zaltrap) into the U.S. market, its price triggered an unusual act of defiance on the part of oncolAogists. Physicians from Memorial Sloan-Kettering
Read More...
Read the complete post at http://healthaffairs.org/blog/2013/02/20/winners-and-losers-from-the-zaltrap-price-discount-unintended-consequences/?utm_source=rss&utm_medium=rss&utm_campaign=winners-and-losers-from-the-zaltrap-price-discount-unintended-consequences
Posted
Feb 20 2013, 10:46 AM
by
Health Affairs Blog
Filed under: All Categories, Consumers, Policy, Insurance, Payment, Physicians, Health Care Costs, Medicare, Pharma, Hospitals, Medicaid